21:05 , Jun 20, 2019 |  BC Extra  |  Company News

Beyond Keytruda: Merck details plans for future growth

Merck is looking beyond its blockbuster cancer drug Keytruda pembrolizumab to late-stage programs in infectious disease, vaccines and chronic indications to help the pharma weather any revenue shortcomings when its diabetes drug Januvia sitagliptin comes...
17:52 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibition of VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 to treat tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Mouse studies suggest inhibiting VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 could help treat tuberculosis (TB). In a mouse model of TB, expression of mutant VEGF-A with...
14:00 , Apr 17, 2019 |  BC Innovations  |  Emerging Company Profile

Nocion: Targeting pain neurons and nothing else

With a $27 million series A co-led by Canaan and F-Prime Capital announced Wednesday, Nocion thinks it could replace opioids in a range of tissue-localized indications, starting with cough. The company is aiming to minimize...
16:00 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest inhibiting P2RX7 could help treat autism. In a mouse model of autism, systemic knockout of P2RX7 or a tool compound P2RX7 inhibitor tool decreased social deficits, sensorimotor coordination impairment and...
17:31 , Sep 26, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A SNP on P2RX7 could help predict outcomes in heart transplant patients. In 102 heart transplant patients, P2RX7 genotyping identified an association between a SNP on P2RX7 (rs3751143) and the risk of rapidly...
16:13 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Mouse and rat studies suggest inhibiting PANX1 or its activator P2RX7 in spinal microglia, or an antibody-drug conjugate (ADC) targeting the microglia, could help treat joint pain. In spinal cord samples from a...
21:12 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Graft rejection Patient sample and mouse studies suggest inhibiting P2RX7 could help treat transplant rejection. In blood samples from liver transplant patients, monocyte levels of P2RX7 were higher in patients who rejected their transplants...
21:36 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Bellus Health raises C$20M in follow-on

On Dec. 12, Bellus Health Inc. (TSX:BLU) raised C$20 million ($15.6 million) through the sale of 52.6 million shares at C$0.38 in a follow-on. The price values the company at C$45.4 million ($35.4 million). Bloom...
15:48 , May 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Patient samples, cell culture, and mouse studies suggest P2RX7 inhibitors could help treat diabetic nephropathy. In glomeruli samples from diabetes patients, P2RX7 expression was higher in patients with nephropathy than in patients without...
23:07 , Jan 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Inflammation; dermatology; renal

INDICATION: Inflammation; dermatitis; glomerulonephritis Cell culture, human sample and mouse studies identified anti- P2RX7 nanobodies that could help treat allergic contact dermatitis, glomerulonephritis and other inflammatory diseases. Screening of nanobody libraries from P2RX7-immunized llamas, engineering...